title: Stably transfected adherent cancer cell models with decreased expression of 5'-nucleotidase cN-II.
abstract: The 5'-nucleotidase cN-II has been shown to be associated with the sensitivity to nucleoside analogues, the survival of cytarabine treated leukemia patients and to cell proliferation. Due to the lack of relevant cell models for solid tumors, we developed four cell lines with low cN-II expression and characterized them concerning their in vitro sensitivity to cancer drugs and their intracellular nucleotide pools. All four cell models had an important decrease of cN-II expression but did not show modified sensitivity, cell proliferation or nucleotide pools. Our cell models will be important for the study of the role of cN-II in human cancer cells.
authors.affiliation: a Université de Lyon , Lyon , France.|b Université de Lyon , Lyon , France.|c INSERM U1052, Centre de Recherche en Cancérologie de Lyon , Lyon , France.|d CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon , Lyon , France.|e Centre Léon Bérard , Lyon , France.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Bricard
authors.affiliation: a Université de Lyon , Lyon , France.|b Université de Lyon , Lyon , France.|c INSERM U1052, Centre de Recherche en Cancérologie de Lyon , Lyon , France.|d CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon , Lyon , France.|e Centre Léon Bérard , Lyon , France.
authors.forename: Emeline
authors.initials: E
authors.lastname: Cros-Perrial
authors.affiliation: a Université de Lyon , Lyon , France.|b Université de Lyon , Lyon , France.|f Hospices Civils de Lyon , Lyon , France.
authors.forename: Christelle
authors.initials: C
authors.lastname: Machon
authors.affiliation: a Université de Lyon , Lyon , France.|b Université de Lyon , Lyon , France.|c INSERM U1052, Centre de Recherche en Cancérologie de Lyon , Lyon , France.|d CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon , Lyon , France.|e Centre Léon Bérard , Lyon , France.|f Hospices Civils de Lyon , Lyon , France.
authors.forename: Charles
authors.initials: C
authors.lastname: Dumontet
authors.affiliation: a Université de Lyon , Lyon , France.|b Université de Lyon , Lyon , France.|c INSERM U1052, Centre de Recherche en Cancérologie de Lyon , Lyon , France.|d CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon , Lyon , France.|e Centre Léon Bérard , Lyon , France.
authors.forename: Lars Petter
authors.initials: LP
authors.lastname: Jordheim
mesh_terms: D015720:5'-Nucleotidase / Q000235:genetics / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003854:Deoxyribonucleotides / Q000378:metabolism; D015870:Gene Expression; D055785:Gene Knockdown Techniques; D006801:Humans; D020128:Inhibitory Concentration 50; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics; D012265:Ribonucleotides / Q000378:metabolism; D014162:Transfection
chemical_list: D000970:Antineoplastic Agents; D003854:Deoxyribonucleotides; D034741:RNA, Small Interfering; D012265:Ribonucleotides; D015720:5'-Nucleotidase; C508048:NT5C2 protein, human
keywords: Cell models; cN-II, shRNA; cancer; nucleotides